How This Evidence Evolved
Allergen Immunotherapy Modalities
From Subcutaneous Injections to Oral and Epicutaneous Delivery
Timeline
Early observations and pilot data that first suggested a new direction
Position paper on SLIT
Rhinoconjunctivitis daily symptom score over 5 grass pollen seasons (3 treatment years plus 2 follow-up years): 25% to 36% lower with SQ grass tablet vs placebo (P <= .004); weighted combined score 27% to 41% lower (P <= .003)
Very severe SCIT systemic reaction rate in the reviewed surveillance data: approximately 1 per million injections
Landmark RCTs and pivotal trials that established the evidence base
Combined symptom and medication score during grass season
Toleration of ≥600mg peanut protein at exit food challenge without dose-limiting symptoms
January 2020 FDA approval of peanut oral immunotherapy; first approved food-allergy therapy
Postmarketing safety analysis: 1509 suspected SLIT-tablet cases; 59.17% of reported adverse events non-serious
Follow-up studies, subgroup analyses, and real-world validation
Responder rate (eliciting-dose threshold) at month 12: 35.3% peanut patch vs 13.6% placebo (difference 21.7%; 95% CI 12.4%-29.8%; P < .001; prespecified 15% lower CI bound not met)
Review of vaccine approaches, including hypoallergenic derivatives, peptides, adjuvants and administration routes
Integration into clinical practice guidelines and recommendations
Current standard of care and ongoing research directions
Review of intralymphatic, epicutaneous, recombinant, peptide and biologic-combination approaches
Review of biomarkers and novel allergen vaccines; further predictive-biomarker research recommended
Landmark Trials in This Story
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009
Position paper on SLIT
SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.
Rhinoconjunctivitis daily symptom score over 5 grass pollen seasons (3 treatment years plus 2 follow-up years): 25% to 36% lower with SQ grass tablet vs placebo (P <= .004); weighted combined score 27% to 41% lower (P <= .003)
Anaphylaxis: still a ghost behind allergen immunotherapy.
Very severe SCIT systemic reaction rate in the reviewed surveillance data: approximately 1 per million injections
Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE
Combined symptom and medication score during grass season
AR101 Oral Immunotherapy for Peanut Allergy
Toleration of ≥600mg peanut protein at exit food challenge without dose-limiting symptoms
Oral immunotherapy for treatment of peanut allergy.
January 2020 FDA approval of peanut oral immunotherapy; first approved food-allergy therapy
Post-marketing safety evaluation and objective benefit-risk assessment of sublingual immunotherapy tablets in allergic rhinitis.
Postmarketing safety analysis: 1509 suspected SLIT-tablet cases; 59.17% of reported adverse events non-serious
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.
Responder rate (eliciting-dose threshold) at month 12: 35.3% peanut patch vs 13.6% placebo (difference 21.7%; 95% CI 12.4%-29.8%; P < .001; prespecified 15% lower CI bound not met)
Novel immunotherapy vaccine development.
Review of vaccine approaches, including hypoallergenic derivatives, peptides, adjuvants and administration routes
Novel Approaches to Allergen Immunotherapy for Respiratory Allergies.
Review of intralymphatic, epicutaneous, recombinant, peptide and biologic-combination approaches
Recent advances in allergen immunotherapy.
Review of biomarkers and novel allergen vaccines; further predictive-biomarker research recommended
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.